Answers are grounded in this paper and cite their sources.
Objective This study aimed to investigate the neuroprotective effects of Shao-Di-Pa-Ning Decoction (SDPND) in a Parkinson’s disease (PD) mouse model and explore its potential molecular mechanisms, with a particular focus on the regulation of SIRT3/PINK1/Parkin-associated mitochondrial quality-control signaling. Methods Ten-month-old male A53T mice were randomly assigned to the PD model group, SDPND low-, medium-, and high-dose groups (6.956, 13.91, and 27.82 g crude-herb equivalents/kg/day, respectively), and the levodopa/benserazide hydrochloride (LBHT) group (0.1 g/kg/day). Age-matched male C57BL/6 J mice served as the control group. All interventions were administered orally for four consecutive weeks. Behavioral tests, including the pole-climbing and hanging tests, were performed to evaluate motor dysfunction. Immunohistochemistry (IHC) and TUNEL staining were conducted to assess dopaminergic neuronal injury and apoptosis in the substantia nigra. Based on the pharmacological effects observed in the SDPND medium-dose group (13.91 g/kg/day), substantia nigra tissues from control, A53T model, and SDPND medium-dose-treated mice were subjected to transcriptomic sequencing. Differentially expressed genes were identified and analyzed using GO, KEGG, and PPI network analyses to explore the potential molecular mechanisms underlying SDPND-mediated neuroprotection. The effects of SDPND on mitochondrial function, oxidative stress, and mitophagy-related signaling were further validated using transmission electron microscopy (TEM), JC-1 staining, biochemical assays, quantitative real-time PCR (RT-qPCR), and Western blotting. Results SDPND significantly improved motor deficits in A53T mice, increased tyrosine hydroxylase (TH) expression, reduced abnormal α-synuclein accumulation, and attenuated DNA fragmentation in the substantia nigra. Transcriptomic analysis combined with GO, KEGG, and PPI analyses identified mitochondrial function and mitophagy-related pathways as potential targets of SDPND intervention, with SIRT3 emerging as a key regulatory candidate. Further validation demonstrated that SDPND improved mitochondrial morphology, enhanced mitochondrial membrane potential and ATP levels, reduced oxidative stress levels, and increased SIRT3, PINK1, and Parkin expression and the LC3-II/LC3-I ratio, while reducing p62 expression. Conclusion SDPND ameliorates motor dysfunction and neuronal injury in A53T mice. These neuroprotective effects are functionally associated with the modulation of SIRT3/PINK1/Parkin-related signaling and mitophagy-associated markers, alongside improved mitochondrial homeostasis and antioxidant capacity. These findings provide experimental evidence supporting the neuroprotective potential of SDPND, warranting further targeted mechanistic validation.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: